Search

Your search keyword '"ALLEGRO R"' showing total 46 results
Start Over Author "ALLEGRO R" Language undetermined
46 results on '"ALLEGRO R"'

1. SERENOA REPENS, LICOPENE E SELENIUM VS. TAMSULOSINA PER IL TRATTAMENTO DEI LUTS: UNO STUDIO ITALIANO MULTICENTRICO RANDOMIZZATO COMPARATIVO TRA LA MONOTERAPIA O LA COMBINAZIONE (PROCOMB STUDY)

Author

Morgia, G., Russo, G., Voce, S., Palmieri, F., Gentile, M., Giannantoni, A., Blefari, F., Carini, M., Minervini, A., Ginepri, A., Salvia, G., Vespasiani, G., Cimino, S., Allegro, R., Collura, Z., Fragalà, E., Arnone, S., and Pareo, R.

Subjects
SERENOA REPENS, LICOPENE E SELENIUM ,TAMSULOSINA , LUTS:, PROCOMB STUDY
Published
2014

2. RISULTATI DI UNO STUDIO RANDOMIZZATO SULLA TOSSICITÀ E SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR DI CARCINOMA VESCICALE SUPERFICIALE

Author

ALTIERI V, MORGIA G, MOTTA M, ANNESE P, CARRIERI G, DI LALLO A, SBLENDORIO D, SALZANO L, BROTZA D, RUGGIERO G, SAITA A, CACCIATORE M, SIMONE NS, IADEVAIA M, VACIRCA F, SELVAGGI FP, PIRRITANO D, BIZZINI A, PEPE P, PAVONE MACALUSO M, ALLEGRO R. E. I. MEMBRI DEL GSTU, SERRETTA, Vincenzo, MELLONI, Darvinio, SCUTO, Fabio, ZITO, Anna, GALLO, Alessia, ALTIERI V, SERRETTA V, MORGIA G, MELLONI D, SCUTO F, MOTTA M, ZITO A, ANNESE P, CARRIERI G, DI LALLO A, GALLO A, SBLENDORIO D, SALZANO L, BROTZA D, RUGGIERO G, SAITA A, CACCIATORE M, SIMONE NS, IADEVAIA M, VACIRCA F, SELVAGGI FP, PIRRITANO D, BIZZINI A, PEPE P, PAVONE-MACALUSO M, and ALLEGRO R E I MEMBRI DEL GSTU

Published
2005

3. Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale

Author

SERRETTA, Vincenzo, MORGIA G, ALTIERI V, MELLONI, Darvinio, RUGGIRELLO A, COSENTINO V, CINDOLO L, BORRUSO L, IADEVAIA M, VACCARELLA, Gianpaolo, CAMMARATA C, Armenio, Angelo, SARACINO A, NICOLOSI D, FALVO F, LO PRESTI, Davide, GENTILE, Monica, SIRAGUSA A, PAOLA Q, MASALA A, DELIA A, ARAGONA F, SPAMPINATO A, ALLEGRO R. E. I. MEMBRI DEL GSTU, SERRETTA V, MORGIA G, ALTIERI V, MELLONI D, RUGGIRELLO A, COSENTINO V, CINDOLO L, BORRUSO L, IADEVAIA M, VACCARELLA G, CAMMARATA C, ARMENIO A, SARACINO A, NICOLOSI D, FALVO F, LO PRESTI D, GENTILE M, SIRAGUSA A, PAOLA Q, MASALA A, DELIA A, ARAGONA F, SPAMPINATO A, and ALLEGRO R E I MEMBRI DEL GSTU

Published
2005

7. Environmental factors in superficial bladder cancer. Preliminary report of a prospective study

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, MELLONI, Darvinio, GALLO, Alessia, ALTIERI V, MORGIA G, PAVONE MACALUSO M, DI LALLO A, SAITA A, MOTTA M, SALZANO L, CINDOLO L, ZITO A. A. STUDY FROM GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA, V, ALTIERI, V, MORGIA, G, ALLEGRO, R, PAVONE MACALUSO, M, MELLONI, D, DI LALLO, A, GALLO, A, SAITA, A, MOTTA, M, CINDOLO, L, SALZANO, L, ZITO, A GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA V, ALTIERI V, MORGIA G, ALLEGRO R, PAVONE-MACALUSO M, MELLONI D, DI LALLO A, GALLO A, SAITA A, MOTTA M, SALZANO L, CINDOLO L, and ZITO A A STUDY FROM GRUPPO STUDI TUMORI UROLOGICI GSTU

Published
2004

8. TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Years

Author

Michele Pavone-Macaluso, Carlo Pavone, G. Daricello, Rosalinda Allegro, Vincenzo Serretta, G.B. Ingargiola, SERRETTA V, PAVONE C, INGARGIOLA GB, DARICELLO G, ALLEGRO R, and PAVONE-MACALUSO M

Subjects
Adult, medicine.medical_specialty, Time Factors, Urology, Population, Intravesical adjuvant chemotherapy, Disease-Free Survival, Settore MED/24 - Urologia, T1G3 bladder cancer, medicine, Adjuvant therapy, Humans, education, Survival rate, Aged, Neoplasm Staging, Aged, 80 and over, Carcinoma, Transitional Cell, education.field_of_study, Urinary bladder, Bladder cancer, business.industry, Middle Aged, medicine.disease, Surgery, Survival Rate, medicine.anatomical_structure, Urinary Bladder Neoplasms, Chemotherapy, Adjuvant, Tumor progression, Concomitant, Disease Progression, Urologic Surgical Procedures, Neoplasm Recurrence, Local, business, Conservative treatment, Follow-Up Studies, Epirubicin, medicine.drug
Abstract

OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study if Tis, recurrent T1G3 or invasive tumor were detected during treatment or thereafter. Adjuvant therapy, recurrence and progression were considered in multivariate analysis regarding recurrence, progression and survival respectively. RESULTS: Observation period was up to 240 months with a minimum of 2 years in 112 patients (82%). Seventy patients (51%) recurred. The recurring tumor was again a T1G3 in 22 (16%) patients. Thirteen patients (9.5%) progressed. The 5-year progression-free survival rate was 90%. Median progression-free survival was 149 months. Twenty-two patients (16%) died, 9 (6.6%) of whom due to bladder cancer. Median overall survival was 155 months. The 3- and 5-year disease-free overall survival rates were 89% and 80% respectively. Ten cystectomies (7.3%) were performed. In conclusion, 123 patients (90%) maintained their intact bladder with a mean disease-free overall survival of 104 months. The sequential combination of MMC and EPI adjuvant therapy resulted more effective to be than single drug chemotherapy on recurrence rate (p=0.0021) but had no impact upon progression (p=0.127) and specific survival (p=0.163). Progression (p

Published
2004
Full Text
View/download PDF

9. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia

Author

Francesco Ferraù, Giuseppe Morgia, Vincenzo Altieri, Vincenzo Serretta, D. Melloni, Federico Nicolosi, Vittorio Gebbia, Gaetano De Grande, Rosalinda Allegro, Rosaria Mazza, Serretta, V, Altieri, V, Morgia, G., Nicolosi, F., De Grande, G., Mazza, R., Melloni, D., Allegro, R., Ferraù, F., and Gebbia, V.

Subjects
Oncology, Male, medicine.medical_specialty, Bicalutamide, medicine.drug_class, Visual analogue scale, Urology, Breast pain, Antineoplastic Agents, Antiandrogen, Statistics, Nonparametric, law.invention, Tosyl Compounds, Prostate cancer, stomatognathic system, Randomized controlled trial, law, Internal medicine, Nitriles, medicine, Humans, Anilides, skin and connective tissue diseases, Aged, Aged, 80 and over, business.industry, Estrogen Antagonists, Prostatic Neoplasms, Middle Aged, medicine.disease, Tamoxifen, Treatment Outcome, Gynecomastia, Chemotherapy, Adjuvant, medicine.symptom, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

BACKGROUND: Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of BEs when diagnosed. The results of a randomized study comparing TAM prophylaxis vs. TAM therapy are presented. METHODS: One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs. TAM 10 mg daily starting simultaneously with bicalutamide (arm B). TAM was administered for up to 1 year. BEs were evaluated by a self-administered visual analogue scale. Neither ultrasonography nor calipers were used to measure the degree of gynecomastia. RESULTS: In arm A, BEs showed a prevalence, increasing with time up to 78.3%. After therapy with TAM they persisted in 27.7% of cases. Two patients (3%) interrupted TAM therapy because of dizziness, and 3 patients (4%) interrupted bicalutamide therapy because of painful gynecomastia. In arm B, the prevalence of BEs was 35% after 12 months of therapy. The difference in BEs between the 2 arms was statistically significant (P < .0001). The differences in prevalence of gynecomastia and breast pain between the 2 arms both favored TAM prophylaxis (P < .0001 and P < .001, respectively). Up to 35% of patients had BEs of low intensity, never requiring bicalutamide withdrawal. Two patients (3%) interrupted the treatment because of gastrointestinal intolerance. No difference emerged between the 2 arms in terms of prostate-specific antigen (PSA) response, plasma testosterone levels, and tumor progression. CONCLUSION: Bicalutamide-induced BEs can be prevented to a significant degree by prophylaxis with TAM 10 mg/day or effectively treated with TAM therapy 20 mg/day. Persisting BEs are of higher intensity after therapy than after prophylaxis.

Published
2011

10. The Multicriteria Electre III Model Applied to the Evaluation of the Placement of University Graduates

Author

Ornella Giambalvo, Rosalinda Allegro, Attanasio, M, Capursi, V, Allegro, R, and Giambalvo, O

Subjects
Engineering, Management science, business.industry, Corporate governance, Financial autonomy, Effective management, Settore SECS-S/05 - Statistica Sociale, ELECTRE, Rationalization (economics), business, Curriculum, University system, Job placement, multicriteria models, ranking
Abstract

During the last years the Italian university system has been undergoing a reform process regarding issues of governance such as the progressive financial autonomy of the University (art. 5, law 537/24 December 1993) and the reshape of the academic curricula (law 509/99 and 270/04). The most obvious result of this complex process has been the challenging attempt to manage a necessary change in a context of limited financial resources. In order to encompass the composite features of an efficient and effective management of resources, features of high relevance for the full accomplishment of the reform benchmarks, one has to take into account the academic organisation’s objectives, so that to use tools and methods able to support decisions and, thus, allowing a rationalization of the decision-making processes.

Published
2010
Full Text
View/download PDF

11. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital

Author

Vincenzo Altieri, M. Napoli, Darvinio Melloni, Siragusa A, Mario Falsaperla, Giuseppe Morgia, Vincenzo Serretta, Gaetano De Grande, Rosalinda Allegro, SERRETTA V, ALTIERI V, MORGIA G, SIRAGUSA A, DE GRANDE G, NAPOLI M, FALSAPERLA M, MELLONI D, and ALLEGRO R

Subjects
Oncology, Male, medicine.medical_specialty, Hormone refractory, Oral chemotherapy, Urology, Psa response, Administration, Oral, Antineoplastic Agents, Adenocarcinoma, Prostate cancer, hormone-refractory prostate carcinoma, Oral chemotherapy, Internal medicine, medicine, Estramustine phosphate, Humans, Etoposide, Aged, Aged, 80 and over, business.industry, Prostatic Neoplasms, Prostate carcinoma, Middle Aged, medicine.disease, Hospitalization, Estramustine, Patient Compliance, business, medicine.drug, Hormone
Abstract

Objectives: To investigate the safety and efficacy in terms of PSA response of a low-dose oral combination of estramustine phosphate (EMP) and etoposide (VP16) in hormone- refractory prostate cancer (HRPC) patients. Well-tolerated outpatient chemotherapy regimens for patients unfit and/or unwilling to be admitted to hospital are needed. Methods: Fifty-six HRPC patients with metastatic disease (median age 75 years) were randomized between arm A (daily oral EMP 10 mg/kg, in 3 doses) and arm B (28-day cycle with low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m2 once daily on days 1 through 14). Baseline characteristics between the two groups were similar. LHRH therapy was maintained. Anti- androgen was stopped 1 month before entry. Results: The low-dose combination was better tolerated, with a significant advantage in terms of time to treatment interruption for any reason (p = 0.01) or toxicity (6 vs. 12 months, p = 0.02). A trend in favour of arm B was evident in terms of PSA reduction (41.4 vs. 15%), performance status and pain improvement. Hospital admission due to toxicity was never required for arm B patients and there were no treatment-related deaths. Conclusions: Low-dose oral combination of EMP and VP16 might represent a treatment option for patients unfit for i.v. chemotherapy. This regimen requires minimal toxicity monitoring when administered at home for prolonged periods.

Published
2008

13. Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante

Author

ALLEGRO, Rosalinda, SERRETTA, Vincenzo, MELLONI, Darvinio, TESTA, Giuseppe, Armenio, Angelo, GALLO, Alessia, ALTIERI, V, MORGIA, G, ANNESE, P, RUGGIRELLO, A, DI LALLO, A, MAGNO, C, CAMMARATA, C, SALZANO, L, SIRAGUSA, A, D'ELIA, A, MOTTA, M, COSENTINO, C, BORRUSO, L, BARTOLOTTA, A, SELVAGGI, FP, FALVO, F, ARAGONA, F, PAVONE MACALUSO, M., ALLEGRO, R, SERRETTA, V, ALTIERI, V, MORGIA, G, ANNESE, P, RUGGIRELLO, A, DI LALLO, A, MELLONI, D, MAGNO, C, TESTA, G, ARMENIO, A, CAMMARATA, C, SALZANO, L, SIRAGUSA, A, D'ELIA, A, MOTTA, M, COSENTINO, C, BORRUSO, L, BARTOLOTTA, A, SELVAGGI, FP, GALLO, A, FALVO, F, ARAGONA, F, and PAVONE-MACALUSO, M

Published
2006

15. low dose oral chemotherapy for hormone refractory prostate carcnoma.Estramustine phosphate versus estramustine phosphate and etoposide. A randomised phase II study of GSTU Found

Author

SERRETTA, Vincenzo, GALUFFO, Antonino, MELLONI, Darvinio, PAVONE, Carlo, ALLEGRO, Rosalinda, MORGIA G, ALTIERI V, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M. DE GRANDE G, PAVONE MACALUSO M, SERRETTA V, MORGIA G, ALTIERI V, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M DE GRANDE G, GALUFFO A, MELLONI D, PAVONE C, PAVONE MACALUSO M, and ALLEGRO R

Published
2006

16. Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562

Author

SERRETTA, Vincenzo, ALTIERI V, MORGIA G, ALLEGRO, Rosalinda, CAPRA, Massimo, ZITO, Anna, DI LALLO A, ANNESE P, SBLENDORIO D, GALLO, Alessia, CINDOLO L, RUGGIERO G, SIMONE NS, SELVAGGI FP, BATTAGLIA M, VACCARELLA, Gianpaolo, Armenio, Angelo, LO PRESTI, Davide, NICOLOSI D, MELLONI, Darvinio, I. MEMBRI DELLA FONDAZIONE, GSTU, SERRETTA V, ALTIERI V, MORGIA G, ALLEGRO R, CAPRA M, ZITO A, DI LALLO A, ANNESE P, SBLENDORIO D, GALLO A, CINDOLO L, RUGGIERO G, SIMONE NS, SELVAGGI FP, BATTAGLIA M, VACCARELLA G, ARMENIO A, LO PRESTI D, NICOLOSI D, MELLONI D, I MEMBRI DELLA FONDAZIONE, and GSTU

Published
2006

18. Uno sguardo alle famiglie

Author

ALLEGRO, Rosalinda, DARDANONI, Valentino, GIAMBALVO, Ornella, LI DONNI, Paolo, CAPURSI V., GIAMBALVO O., ALLEGRO R, DARDANONI V, GIAMBALVO O, and LI DONNI P

Published
2006

19. ESTRAMUSTINE PHOSPATE VERSUS INTERMITTENT LOW DOSE ORAL COMBINATION OF ESTRAMUSTINE PHOSPATE AND ETOPOSIDE IN HORMONE REFRACTORY PROSTATE CARCINOMA. A PHASE II STUDY OF GSTU FOUND

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, PAVONE, Carlo, MELLONI, Darvinio, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, RUGGIRELLO A, PAVONE MACALUSO M., SERRETTA V, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, ALLEGRO R, RUGGIRELLO A, PAVONE C, MELLONI D, and PAVONE-MACALUSO M

Published
2006

23. STUDIO RANDOMIZZATO SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR CON EPIRUBICINA

Author

SERRETTA, Vincenzo, ALTIERI V, MORGIA G, ALLEGRO, Rosalinda, CAPRA, Massimo, ZITO, Anna, DI LALLO A, ANNESE P, SBLENDORIO D, GALLO, Alessia, CINDOLO L, RUGGIERO G, SIMONE NS, SELVAGGI FP, BATTAGLIA M, VACCARELLA, Gianpaolo, Armenio, Angelo, LO PRESTI, Davide, NICOLOSI D, MELLONI, Darvinio, I. MEMBRI DELLA FONDAZIONE, GSTU, SERRETTA V, ALTIERI V, MORGIA G, ALLEGRO R, CAPRA M, ZITO A, DI LALLO A, ANNESE P, SBLENDORIO D, GALLO A, CINDOLO L, RUGGIERO G, SIMONE NS, SELVAGGI FP, BATTAGLIA M, VACCARELLA G, ARMENIO A, LO PRESTI D, NICOLOSI D, MELLONI D, I MEMBRI DELLA FONDAZIONE, and GSTU

Published
2006

25. Water Chlorination and other environmental factors in bladder cancer. Result of a multicentre study

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, MELLONI, Darvinio, TESTA, Giuseppe, ALTIERI V, MORGIA G, CINDOLO L, DI LALLO A, MAGNO C, SALZANO L, MOTTA M, SAITA A, SELVAGGI FP, ANNUNZIATA G, SBLENDORIO D, PAVONE MACALUSO M, GOUC, GSTU, SERRETTA V, ALTIERI V, MORGIA G, CINDOLO L, ALLEGRO R, DI LALLO A, MELLONI D, MAGNO C, SALZANO L, MOTTA M, SAITA A, SELVAGGI FP, ANNUNZIATA G, TESTA G, SBLENDORIO D, PAVONE-MACALUSO M, GOUC, and GSTU

Published
2005

26. Ruolo della terapia di mantenimento e fattori di rischio ambientale nel carcinoma vescicale superficiale. Pazienti sottoposti a chemioterapia endovescicale adiuvante. Risultati preliminari di uno studio randomizzato su 577 pazienti

Author

GALUFFO, Antonino, SERRETTA, Vincenzo, MELLONI, Darvinio, VACCARELLA, Gianpaolo, Armenio, Angelo, ALLEGRO, Rosalinda, ALTIERI V, MORGIA G, MAGNO C, COSENTINO V, BORRUSO L, MOTTA M, SAITA A, CACCIATORE M, CAMMARATA C, NICOLOSI D, FALVO F, GANGE E, SIRAGUSA A, ARAGONA F, PAOLA Q, SPAMPINATO A, PAVONE MACALUSO M, MEMBRI DEL GSTU, GALUFFO A, SERRETTA V, ALTIERI V, MORGIA G, MELLONI D, MAGNO C, COSENTINO V, BORRUSO L, MOTTA M, SAITA A, CACCIATORE M, VACCARELLA G, CAMMARATA C, ARMENIO A, NICOLOSI D, FALVO F, GANGE E, SIRAGUSA A, ARAGONA F, PAOLA Q, SPAMPINATO A, ALLEGRO R, PAVONE-MACALUSO M, and MEMBRI DEL GSTU

Published
2005

29. Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU)

Author

SERRETTA, Vincenzo, MELLONI, Darvinio, GALUFFO, Antonino, ALLEGRO, Rosalinda, PARRINELLO, Marica, ALTIERI V, MORGIA G, MAGNO C, SIRAGUSA A, MOTTA M, ORESTANO F, BULGARELLA A, DE GRANDE G, PAVONE MACALUSO M, MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA V, ALTIERI V, MORGIA G, MELLONI D, MAGNO C, SIRAGUSA A, MOTTA M, ORESTANO F, BULGARELLA A, DE GRANDE G, GALUFFO A, ALLEGRO R, PARRINELLO M, PAVONE-MACALUSO M, and MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU

Published
2005

30. Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1

Author

MORGIA G, ALTIERI V, MOTTA M, MAGNO C, CHINCOLI S, CACCIATORE M, SIMONE NS, CONTINO G, PIRRITANO D, MASALA A, DELIA A, BULGARELLA A, MAZZA R, RICCI BARBINI V, RAGUSO G, ESPOSITO C, CICALESE V, PAVONE MACALUSO M. E. I. MEMBRI DEL GSTU, SERRETTA, Vincenzo, MELLONI, Darvinio, GALUFFO, Antonino, TESTA, Giuseppe, GENTILE, Monica, ALLEGRO, Rosalinda, MORGIA G, SERRETTA V, ALTIERI V, MELLONI D, GALUFFO A, MOTTA M, TESTA G, MAGNO C, CHINCOLI S, CACCIATORE M, SIMONE NS, CONTINO G, PIRRITANO D, GENTILE M, MASALA A, DELIA A, BULGARELLA A, MAZZA R, RICCI BARBINI V, RAGUSO G, ESPOSITO C, CICALESE V, ALLEGRO R, and PAVONE-MACALUSO M E I MEMBRI DEL GSTU

Published
2005

31. TERAPIA DI II LINEA NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC) CON ESTRAMUSTINA FOSFATO ED ETOPOSIDE. STUDIO DI FASE II DEL GSTU

Author

PARRINELLO, Marica, SERRETTA, Vincenzo, GALUFFO, Antonino, ALLEGRO, Rosalinda, MELLONI, Darvinio, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, ALTIERI V, MORGIA G, MAGNO C, PAVONE MACALUSO M. AND MEMBERS OF GRUPPO STUDIO TUMORI UROLOGICI GSTU ABSTRACT COMUNICAZIONE CONGRESSO SOCIETA SICULO CALABRA DI UROLOGIA TRAPANI, PARRINELLO M, SERRETTA V, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, GALUFFO A, ALLEGRO R, ALTIERI V, MORGIA G, MELLONI D, MAGNO C, and PAVONE-MACALUSO M AND MEMBERS OF GRUPPO STUDIO TUMORI UROLOGICI GSTU ABSTRACT COMUNICAZIONE CONGRESSO SOCIETA SICULO-CALABRA DI UROLOGIA TRAPANI

Published
2005

33. ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO ED ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO. STUDIO RANDOMIZZATO IN FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU)

Author

SERRETTA, Vincenzo, GALUFFO, Antonino, DISPENSA, Nino, ALLEGRO, Rosalinda, PAVONE, Carlo, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, PAVONE MACALUSO M., SERRETTA V, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, GALUFFO A, DISPENSA N, ALLEGRO R, PAVONE C, and PAVONE MACALUSO M

Published
2005

34. La p53 nel tumore vescicale superficiale (Ta-T1, G1-3)

Author

GALUFFO, Antonino, SERRETTA, Vincenzo, VELLA, Marco, ALLEGRO, Rosalinda, PAVONE, Carlo, CATANESE A, PAVONE MACALUSO M., GALUFFO A, SERRETTA V, CATANESE A, VELLA M, ALLEGRO R, PAVONE C, and PAVONE- MACALUSO M

Published
2004

36. Fattori di rischio ambientali nella storia naturale del carcinoma vescicale superficiale

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, MELLONI, Darvinio, VACCARELLA, Gianpaolo, Armenio, Angelo, CURTO, Giuseppe, TESTA, Giuseppe, GALLO, Alessia, ZITO, Anna, MORGIA G, ALTIERI V, MAGNO C, COSENTINO V, BORRUSO L, MOTTA M, SAITA A, BARTOLOTTA A, VACIRCA F, CAMMARATA C, NICOLOSI D, M. NAPOLI, BIZZINI A, ARAGONA F, GANGE E, SPAMPINATO A, PAOLA Q, DI LALLO A, SALZANO L, CARRIERI G, ANNESE P, PAVONE MACALUSO M, MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA V, MORGIA G, ALTIERI V, ALLEGRO R, MELLONI D, MAGNO C, COSENTINO V, BORRUSO L, MOTTA M, SAITA A, BARTOLOTTA A, VACCARELLA G, VACIRCA F, CAMMARATA C, ARMENIO A, NICOLOSI D, M NAPOLI, BIZZINI A, ARAGONA F, GANGE E, SPAMPINATO A, CURTO G, PAOLA Q, DI LALLO A, TESTA G, GALLO A, SALZANO L, CARRIERI G, ANNESE P, ZITO A, PAVONE-MACALUSO M, and MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU

Published
2004

38. Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione –

Author

PAVONE, Carlo, SERRETTA, Vincenzo, GALUFFO, Antonino, VELLA, Marco, ALLEGRO, Rosalinda, MORELLO, Vincenza, PORCASI, Rossana, ANELLO, Gaetano, TOMASINO, RM, PAVONE MANCUSO, M, C PAVONE, SERRETTA V, D ABBADESSA, M VELLA, G ANELLO, R ALLEGRO, V MORELLO, R PORCASI, R M TOMASINO, M PAVONE MACALUSO RUOLO PROGNOSTICO DELLA P NEL TUMORE VESCICALE SUPERFICIALE CORRELAZIONE CON RECIDIVA E PROGRESSIONE CONGRESSO NAZIONALE SIU - MILANO - GIUGNO, PAVONE, C, SERRETTA, V, GALUFFO, A, VELLA, M, ALLEGRO, R, MORELLO, V, PORCASI, R, TOMASINO, RM, PAVONE-MANCUSO, M, and Anello, G.

Published
2004

39. Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studi Tumori Urologici (GSTU)

Author

SERRETTA, Vincenzo, MELLONI, Darvinio, Armenio, Angelo, VACCARELLA, Gianpaolo, ZITO, Anna, GALLO, Alessia, ALLEGRO, Rosalinda, ALTIERI V, MORGIA G, CARRIERI G, DI LALLO A, MAGNO C, VACIRCA F, SALZANO L, CINDOLO L, BIZZINI A, DELIA A, MOTTA M, SBLENDORIO D, SELVAGGI FP, SIMONE NS, ARAGONA F, PAVONE MACALUSO M, I. MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA V, ALTIERI V, MORGIA G, CARRIERI G, DI LALLO A, MELLONI D, MAGNO C, ARMENIO A, VACIRCA F, SALZANO L, CINDOLO L, BIZZINI A, DELIA A, MOTTA M, SBLENDORIO D, VACCARELLA G, ZITO A, SELVAGGI FP, GALLO A, SIMONE NS, ARAGONA F, ALLEGRO R, PAVONE-MACALUSO M, MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU, and I MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU

Published
2004

40. Diagnosi precoce del carcinoma prostatico in sicilia e calabria. Dati preliminare di uno studio osservazionale del GSTU e della SSCU

Author

ALLEGRO, Rosalinda, SERRETTA, Vincenzo, MELLONI, Darvinio, ARAGONA F, MOTTA M, ORESTANO L, CAMMARATA C, MAGNO C, ARAGONA C, PIRRITANO D, PAOLA Q, COSENTINO V, CAPIZZI G, SAITA A, SPAMPINATO A, NICOLOSI D, RACITI G, SALVIA G, RINELLA M, PAVONEMACALUSO M. E. I. MEMBRI DEL GRUPPO STUDIO TUMORI UROLOGICI GSTU E. DELLA SOCIET SICULO CALABRA DI UROLOGIA SSCU, ALLEGRO R, SERRETTA V, ARAGONA F, MOTTA M, ORESTANO L, CAMMARATA C, MELLONI D, MAGNO C, ARAGONA C, PIRRITANO D, PAOLA Q, COSENTINO V, CAPIZZI G, SAITA A, SPAMPINATO A, NICOLOSI D, RACITI G, SALVIA G, RINELLA M, and PAVONEMACALUSO M E I MEMBRI DEL GRUPPO STUDIO TUMORI UROLOGICI GSTU E DELLA SOCIET SICULO-CALABRA DI UROLOGIA SSCU

Published
2004

41. Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma

Author

R. Sanguedolce, Michele Pavone-Macaluso, Carlo Pavone, Rosalinda Allegro, Vincenza Morello, Rosa Maria Tomasino, Marco Vella, Vincenzo Serretta, Rossana Porcasi, Serretta, V, Pavone, C, Allegro, R, Vella, M, Sanguedolce, R, Porcasi, R, Morello, V, Tomasino, RM, and Pavone, M

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Pathology, medicine.medical_treatment, Urology, Settore MED/24 - Urologia, Superficial bladder carcinoma, GP-170, MDR-1, Prognosis, Intravesical chemotherapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Humans, ATP Binding Cassette Transporter, Subfamily B, Member 1, Stage (cooking), Aged, Retrospective Studies, Chemotherapy, Hematology, Urinary bladder, business.industry, General Medicine, Middle Aged, medicine.disease, Prognosis, Drug Resistance, Multiple, Gene Expression Regulation, Neoplastic, Transitional cell carcinoma, medicine.anatomical_structure, Oncology, Urinary Bladder Neoplasms, Chemotherapy, Adjuvant, Drug Resistance, Neoplasm, Chemoprophylaxis, Female, Superficial Bladder Carcinoma, Genes, MDR, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations in grade and stage at recurrence and modifications in GP-170 expression were also studied. No significant correlation between GP-170 expression and G-grade and T-category was found. A significant correlation was detected between GP-170 expression and recurrence (P=0.0383). It showed a biphasic pattern, i.e., tumors that did not express GP-170 had a higher recurrence rate, but high GP-170 levels were also associated with an increasing risk of recurrence. Intravesical chemotherapy did not induce significative variations in GP-170 expression. No correlation was found between progression and GP-170. GP-170 seems to be an independent prognostic factor for recurrence in superficial bladder tumors. A negative GP-170 pattern and high levels of GP-170 are associated with an increasing risk of recurrence but have no impact upon progression. In our experience, GP-170 is neither induced nor modified by intravesical chemotherapy, although it might represent a factor of chemoresistance when strongly expressed.

Published
2002

42. A RANDOMISED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER

Author

L. Salzano, Michele Pavone-Macaluso, N.S. Simone, A. Zito, Rosalinda Allegro, Giuseppe Morgia, A. Di Lallo, Ruggiero G, F. Vacirca, Vincenzo Altieri, Federico Nicolosi, G. Coraci, Fp Selvaggi, D. Melloni, Vincenzo Serretta, P. Annese, Giuseppe Carrieri, SERRETTA V, ALTIERI V, MORGIA G, ANNESE P, CARRIERI G, ZITO A, DI LALLO A, RUGGIERO G, SALZANO L, NICOLOSI F, SIMONE NS, VACIRCA F, PAVONE-MACALUSO M, SELVAGGI FP, CORACI G, ALLEGRO R, and MELLONI D

Subjects
Oncology, medicine.medical_specialty, Schedule, Bladder cancer, Adjuvant chemotherapy, business.industry, Urology, medicine.disease, bladder cancer, EARLY ADJUVANT CHEMOTHERAPY, Internal medicine, medicine, Non muscle invasive, business, Intermediate risk
Abstract

Introduction and Objective: Adjuvant intravesical chemotherapy or BCG immunotherapy after transurethral resection (TUR) is a standard treatment for non–muscle-invasive transitional cell cancer of the bladder (NMI TCCB) at intermediate risk. Although the clinical value of early intravesical adjuvant chemotherapy is well established, the optimal schedule regimen and the role of maintenance is still debated. Methods: Between May 2002 and August 2003, 577 patients, undergoing TUR for NMI TCCB, were recruited. All patients underwent TUR and early (within 6 hours) intravesical chemotherapy with epirubicin at the dose of 80 mg diluted in 60 ml of saline solution. When histology was available, 95 patients were excluded from the study since they were harbouring T1G3, Tis and single and primary Ta G1-G2 tumors. 482 patients with intermediate risk tumors were randomized according 2 different regimens: arm A: 5 more weekly instillations; arm B: 5 more weekly instillations plus monthly instillations for a total of 16 instillations. All patients were submitted 3-monthly for the first 2-years and then 6-monthly to cytology, cystoscopy and biopsy of every suspicious bladder lesion.. Results: Out of 482 randomized patients, 396 are evaluable for toxicity and 392 for efficacy. The tumours were multiple in 318 patients (66.0%) and recurrent in 192 (39.8%). No difference emerged between the 2 arms in relation to tumors’ characteristics. The median follow-up time was 22 months (range: 3-56). Eighty-two (20.9%) patients recurred at a median time of 9 months from TUR and 4 patients (1%). The incidence of recurrences was 24.4% (47/192) in arm A and 18.5% (35/200) in arm B. No difference emerged between the two arms for recurrence rate at 3 months (p=0.06). Statistical analysis demonstrated an advantage in favour of maintenance in terms of recurrence rate at 6 (p=0.01), 9 (p=0.04) and 12 months (p=0.03) and in terms of recurrence-free interval (p=0.03). No difference for toxicity was detected according to treatment schedule. Conclusions: One-year maintenance significantly reduces the risk of tumour recurrence without enhanced toxicity, in patients with intermediate risk NMI TCCB treated with early epirubicin intravesical chemotherapy followed by 5 weekly instillation.

Published
2008
Full Text
View/download PDF

43. THE ROLE OF INTRAVESICAL GLYCOSAMINOGLYCANS IN TOXICITY INDUCED BY ADJUVANT INTRAVESICAL THERAPY: GENETIC LABORATORY EVIDENCE

Author

Serretta, Vincenzo, Alonge, Vincenza, Gesolfo, Cristina Scalici, Tulone, Gabriele, Cangemi, Antonina Graziella, Caruso, Stefano, Russo, Antonino, D Arienzo, Michele, Rosalinda Allegro, Serretta, V., Alonge, V., Scalici Gesolfo, C., Tulone, G., Cangemi, A., Caruso, S., Russo, A., D'Arienzo, M., and Allegro, R.

Subjects
GLYCOSAMINOGLYCANS, BLADDER, TOXICITY, FIBRONECTIN, EGFR, Settore MED/24 - Urologia

44. CHOICE OF ADJUVANT INTRAVESICAL THERAPY IN RECURRING INTERMEDIATE-RISK NMI-BC

Author

Serretta, Vincenzo, Sommatino, Francesco, Romeo, Salvatore, Territo, Angelo, Rosalinda Allegro, Melloni, Darwin, Serretta, V, Sommatino, F, Romeo, S, Territo, A, Allegro, R, and Melloni, D

Subjects
bladder cancer, intravesical chemotherapy, BCG, Settore MED/24 - Urologia
Abstract

Objective: The therapeutic strategy for patients affected by intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy is not definitively established. Only few studies have been published on secondline intravesical therapy. BCG is advocated when intravesical chemotherapy fails and is often repeated. On the other hand, some patients that suffer recurrence repeat intravesical chemotherapy. A retrospective analysis of 179 intermediaterisk patients submitted to second-line intravesical therapy is reported. Patients and Methods: The clinical files of patients affected by intermediate risk NMI-BC and submitted to second-line adjuvant intravesical therapy were reviewed. Patients not receiving at least six instillations of BCG or intravesical chemotherapy after the first diagnosis and again after the transurethral resection (TUR) of the first recurrence were excluded. Only mitomycin c and epirubicin were accepted as chemotherapy. Only patients with intermediaterisk tumors with a recurrence-risk score between 5 and 9 according to the EORTC risk tables and in absence of Tis were selected. A multivariate analysis was performed for recurrence-free survival (RFS) and progression, considering first line intravesical therapy (BCG versus ICH), previous recurrence-free interval, tumor T category, G grade, multiplicity, second-line intravesical therapy (BCG versus ICH) and maintenance regimen. Results: The study included 179 patients. Chemotherapy was administered as first-line therapy in 131 (73.2%) and BCG in 48 (26.8%) patients. Second-line therapy was represented by BCG in 83 (46.4%) and chemotherapy in 96 (53.6%) patients, with maintenance of at least 12 months in 31% and 38% of patients, respectively. Of the 48 patients previously treated by BCG, 40 (83.3%) received BCG again, while of the 131 previously treated by chemotherapy, 88 (67.2%) repeated it and 43 (32.8%) received BCG. At a median follow-up of 29 months after the second TUR, 65 (36.3%) patients experienced recurrence, 25 (30.1%) and 40 (41.7%) after BCG and chemotherapy, respectively. Thirteen patients showed progression at a median interval of 19 months. At multivariate analysis, no statistically significant correlation was detected. Surprisingly, no statistical difference emerged in terms of recurrence-free interval between first- and second-line therapy and between BCG and chemotherapy as second-line therapy at recurrence after chemotherapy (p=0.28) Conclusion: Almost 65% of patients experiencing recurrence after intravesical chemotherapy received intravesical therapy again. No difference in efficacy was detected between firstand second-line therapies or between BCG and chemotherapy given at recurrence after chemotherapy.

45. VISCERAL FAT TISSUE ACTIVITY DOES NOT CORRELATE TO HIGH GRADE PROSTATE CANCER RISK AT BIOPSY

Author

Scurria, Salvatore, Siracusano, Simone, Giacalone, Ninfa, Cangemi, Antonina Graziella, Caruso, Stefano, Rosalinda Allegro, Russo, Antonio, Colombo, Renzo, Serretta, Vincenzo, Scurria, S., Siracusano, S., Giacalone, N., Cangemi, A., Caruso, S., Allegro, R., Russo, A., Colombo, R., and Serretta, V.

Subjects
Metabolic syndrome, visceral fat, prostate cancer, leptin, Settore MED/24 - Urologia

46. RE-TREATMENT BY INTRAVESICAL THERAPY IN RECURRING PATIENTS AFFECTED BY INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC)

Author

Serretta, V., Sommatino, F., Billone, V., Daricello, M., Rosalinda Allegro, Melloni, D., Serretta, V, Sommatino, F, Billone, V, Daricello, M, Allegro, R, and Melloni, D

Subjects
Non muscle invasive bladder cancer, itravesical chemotherapy, BCG
Abstract

Introduction & Objectives: Up to 70% of patients affected by intermediate risk NMI-BC recur after intravesical therapy (IT). The majority of them will be retreated by IT. The therapeutic strategy for these patients is not well defined. BCG is advocated when intravesical chemotherapy (ICH) fails. However, some patients are retreated by ICH and some others repeat BCG adopted as the first treatment. Not many studies have been published on second line IT. A retrospective analysis on 179 intermediate-risk patients undergoing re-treatment by IT is presented. Materials & Methods: The clinical files of patients affected by NMI-BC recurring after TUR and IT and retreated by IT were reviewed. The patients not receiving at least 6 instillations of BCG or ICH after the first diagnosis and again after the TUR of the first recurrence were excluded. Only mitomycin c and epirubicin were accepted as chemotherapy. Only intermediate-risk tumours with a recurrencerisk score between 5 and 9 according to the EORTC Risk Tables and in absence of Tis were selected. A multivariate analysis was performed for recurrence-free interval (RFI) and progression considering, first line IT (BCG versus ICH), previous recurrence free interval, tumour’s T-category, G-grade, multiplicity, second line IT (BCG versus ICH) and maintenance regimen. Results: The study included 179 patients. The first line IT was ICH in 131 (73.2%) and BCG in 48 (26.8%) patients. The median RFI was 16 months. At recurrence, BCG in 83 (46.4%) and ICH in 96 (53.6%) patients were administered, with maintenance of at least 12 months in 31% and 38% of patients respectively. Of the 48 patients previously treated by BCG, 40 (83.3%) received BCG again, while of the 131 previously treated by ICH, 88 (67.2%) received ICH again and 43 (32.8%) BCG. Thus, only 8 patients received ICH at recurrence after BCG. At a median follow-up of 29 months, 65 (36.3%) patients recurred with a median RFI of 15 months, 25 (30.1%) and 40 (41.7%) after BCG and ICH respectively. Thirteen patients showed progression at a median interval of 19 months. At multivariate analysis no statistically significant correlation was detected among the considered parameters. Surprisingly, no statistical difference emerged in terms of RFI between first and second line IT (16 versus 15 months), and between patients receiving BCG or ICH as second line therapy at recurrence after ICH (=0.28). Conclusions: No reduction in RFI emerged in patients with intermediate-risk NMIBC recurring after a first cycle of intravesical therapy and retreated by intravesical chemotherapy or BCG. In patients recurring after intravesical chemotherapy, intravesical chemotherapy and BCG, as a second line therapy, resulted equally effective in preventing recurrence.

Catalog

Books, media, physical & digital resources
See catalog results